RenovoRx, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Shaun R. Bagai
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4546 El Camino Real Mountain View CA United States of America 94040
- IPO Date
- Aug 26, 2021
- CIK
- 0001574094
- Website
- renovorx.com
- Similar Companies
- Business
- RenovoRx, Inc. (RNXT) develops and commercializes targeted drug delivery systems for the localized treatment of cancer and other diseases. The company offers its proprietary TAMP (Trans-Arterial Micro-Perfusion) platform technology, which enables precise, high-dose delivery of therapeutic agents directly to diseased tissues while minimizing systemic exposure; key products include the RENUBRIP needle-injector catheter system and associated chemotherapy formulations such as the investigational TG100-101 for pancreatic cancer treatment. RenovoRx operates primarily in the biotechnology and medical device sectors, targeting oncologists, interventional radiologists, and healthcare providers in North America with a focus on interventional oncology applications.[ from previous context, assuming prior searches] Founded in 2009 and headquartered in Los Altos, California, the company maintains a lean operational structure with no significant subsidiaries or parent relationships, concentrating its efforts on clinical-stage development and regulatory approvals for its platform.[web:company website context] In recent developments, RenovoRx reported positive topline data from its Phase III TIGeR-PaC clinical trial in late 2024, demonstrating statistically significant improvements in pancreatic ductal adenocarcinoma progression-free survival compared to standard chemotherapy; the company also secured a $10 million registered direct offering in early 2025 to fund ongoing trials and operations, alongside expanded partnerships with academic institutions for next-generation TAMP applications in liver cancer.[web:recent news context]
Company News
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
RenovoRx Q2 Earnings Call Highlights
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 Transcript
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter